MaxCyte (NASDAQ:MXCT) Given New $5.00 Price Target at Craig Hallum

MaxCyte (NASDAQ:MXCT) had its price objective decreased by Craig Hallum from $7.00 to $5.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Wall Street Zen lowered shares of MaxCyte from a “hold” rating to a “sell” rating in a research note on Monday. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, MaxCyte has an average rating of “Hold” and a consensus price target of $5.50.

MaxCyte Stock Down 6.8%

MXCT stock opened at $0.69 on Wednesday. The business has a 50 day moving average price of $0.86 and a 200 day moving average price of $1.32. The stock has a market cap of $73.56 million, a price-to-earnings ratio of -1.60 and a beta of 1.22. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $3.10.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $6.76 million during the quarter, compared to the consensus estimate of $9.16 million. MaxCyte had a negative return on equity of 21.60% and a negative net margin of 135.14%. As a group, sell-side analysts anticipate that MaxCyte will post -0.42 EPS for the current year.

Hedge Funds Weigh In On MaxCyte

A number of hedge funds and other institutional investors have recently made changes to their positions in MXCT. BNP Paribas Financial Markets raised its stake in MaxCyte by 39.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock valued at $57,000 after acquiring an additional 10,263 shares during the last quarter. Kwmg LLC lifted its position in MaxCyte by 75.8% during the 3rd quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after acquiring an additional 11,135 shares during the period. Prudential Financial Inc. purchased a new position in shares of MaxCyte in the 2nd quarter valued at approximately $26,000. State of Wyoming purchased a new position in shares of MaxCyte in the 2nd quarter valued at approximately $38,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of MaxCyte in the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 68.81% of the company’s stock.

MaxCyte News Summary

Here are the key news stories impacting MaxCyte this week:

• Positive Sentiment: Company gave 2026 revenue guidance of $30M–$32M and highlighted upcoming commercial milestones (ExPERT DTx launch and SPL program progress), which provides a directional growth story for 2026. MaxCyte outlines $30M–$32M 2026 revenue target
• Positive Sentiment: Strong cash position — $155.6M in cash, equivalents and investments at year-end and an expected minimum of ~$136M at end-2026 — which lowers near-term financing risk and supports execution of product/commercial milestones. MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Earnings-call and transcript coverage is available (multiple transcripts) — useful for listeners to parse management commentary and cadence on commercialization timing, but the transcripts themselves don’t change fundamentals. SA: Q4 2025 Earnings Call Transcript InsiderMonkey: Q4 2025 Transcript
• Neutral Sentiment: Multiple short-interest notices appeared today but the published figures are internally inconsistent/zeroed (NaN/0), suggesting data noise rather than a clear short-squeeze or covering signal; treat with caution.
• Negative Sentiment: Revenue missed analyst estimates: Q4 revenue ~ $6.75–7.3M vs. consensus ~ $9.16M — the top-line shortfall is the main near-term negative catalyst pressuring the stock. MarketBeat: Q4 results
• Negative Sentiment: Analyst price-target cut: Craig Hallum lowered its PT from $7.00 to $5.00 (while retaining a Buy), which reduces upside expectations and can sap momentum. Benzinga PT cut report

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.